SB297006 structure
|
Common Name | SB297006 | ||
---|---|---|---|---|
CAS Number | 58816-69-6 | Molecular Weight | 342.34600 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C18H18N2O5 | Melting Point | 121 °C | |
MSDS | Chinese USA | Flash Point | N/A | |
Symbol |
GHS07, GHS09 |
Signal Word | Warning |
Use of SB297006SB297006 is a CCR3 antagonist, which significantly inhibits proliferation and neurosphere formation in CCL11-treated neural progenitor cells. |
Name | sb 297006 |
---|---|
Synonym | More Synonyms |
Description | SB297006 is a CCR3 antagonist, which significantly inhibits proliferation and neurosphere formation in CCL11-treated neural progenitor cells. |
---|---|
Related Catalog | |
Target |
CCR3[1] |
In Vitro | SB297006 is a CCR3 antagonist, significantly inhibits proliferation and neurosphere formation in CCL11-treated neural progenitor cells (NPCs) at 100 μM[1]. |
Cell Assay | To evaluate CCR3 blocking, neural progenitor cells (NPCs) are incubated with the CCR3 antagonist SB297006 (100 μM) for 30 minutes and then stimulated with CCL11 (2 μg/mL). After 3 days of culture, NPCs are subjected to CCK-8 assays[1]. |
References |
Melting Point | 121 °C |
---|---|
Molecular Formula | C18H18N2O5 |
Molecular Weight | 342.34600 |
Exact Mass | 342.12200 |
PSA | 101.22000 |
LogP | 3.41310 |
Symbol |
GHS07, GHS09 |
---|---|
Signal Word | Warning |
Hazard Statements | H302-H400 |
Precautionary Statements | P273 |
RIDADR | UN 3077 9 / PGIII |
Precursor 0 | |
---|---|
DownStream 1 | |
CCR3 antagonists: a survey of the patent literature.
Expert Opin. Ther. Pat. 19(8) , 1109-32, (2009) Since the mid-1990s, there has been significant effort invested in the discovery and clinical development of CC chemokine receptor-3 (CCR3) antagonists as potential therapeutics for airway disease.A p... |
|
Cytokine modulators as novel therapies for asthma.
Annu. Rev. Pharmacol. Toxicol. 42 , 81-98, (2002) Cytokines play a critical role in orchestrating and perpetuating inflammation in asthmatic airways and several specific cytokine and chemokine inhibitors are now in development for the treatment of as... |
n-benzoyl-4-nitroaniline ethyl ester |